Validation of the Efficacy of Air Purifiers in Indoor Environment and Allergic Symptoms in Allergic Rhinitis Patients
Launched by YONSEI UNIVERSITY · Mar 17, 2025
Trial Information
Current as of April 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether air purifiers can help reduce symptoms in adults with allergic rhinitis, which is a condition that makes it hard to breathe due to allergies, often triggered by things like dust or pet dander found indoors. The trial is open to adults aged 19 to 60 who have been diagnosed with moderate to severe allergic rhinitis and currently need medication to manage their symptoms. To participate, you must spend a lot of time at home, be able to read and write in Korean, and agree to take part in the study voluntarily.
Participants will be divided into two groups: one will use a real air purifier that filters out allergens, and the other will use a fake air purifier that doesn’t clean the air. Each participant will use their assigned device for four weeks, take a two-week break, and then switch devices for another four weeks. Throughout the study, participants will need to visit the clinic three times, and the whole process will take about five months. This trial aims to see if using the air purifier can truly improve the symptoms of allergic rhinitis for those who struggle with it daily.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adults aged 19 to 60
- • A person with moderate-severe persistent allergic rhinitis diagnosed by an allergy specialist or otolaryngologist and maintained without any change in treatment for more than one month
- • Total nasal symptom Score ≥ 8
- • Patients with allergic rhinitis caused by indoor inhalation antigen antigens (House dust mites ± If the wheal size of the pet skin test is greater than 3mm or the concentration of specific IgE measured by ImmunoCAP ≥ 0.35 kUA/L)
- • A person who spends at least 8 hours/day per week in the home where the cleaner will be installed
- • A person with a wi-fi installed in the home where the purifier will be installed
- • A person who can read and write in Korean
- • A person who fully explains the contents, decides to participate in the study according to his/her free will, and signs a written consent form approved by each agency IRB
- Exclusion Criteria:
- • Patients sensitized to seasonal antigens (tree, grass or weed pollen)
- • Rhinitis patients caused by causes other than allergic rhinitis (drug rhinitis, vascular rhinitis, infectious rhinitis, etc.)
- • Anyone who has required more than 2 weeks of systemic steroid use in the last 3 months
- • A person taking antihistamines for reasons other than rhinitis (chronic urticaria, etc.)
- • Those with anatomical abnormalities that cause nasal congestion, such as non-segmental curvature and non-segmental species
- • A person who has a plan to move during the study period or is scheduled to leave where air purifiers are installed for at least five consecutive days (e.g., travel, business trip, etc.)
- • A person who has already used an air purifier within the last three months
- • Pregnant women, lactating women, persons lacking decision-making ability, persons accommodated in facilities
- • A person whose researcher is deemed unfit to participate in clinical research due to other reasons
About Yonsei University
Yonsei University, a prestigious institution located in South Korea, is renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Yonsei University leverages its extensive expertise and innovative approaches in various fields of medicine to conduct rigorous clinical trials aimed at improving patient outcomes and advancing healthcare solutions. The university's robust infrastructure, multidisciplinary collaboration, and adherence to ethical standards ensure the integrity and reliability of its research initiatives, making it a key player in the global clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Kyung Hee Park
Principal Investigator
Yonsei University Health System, Severance Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported